XML 23 R12.htm IDEA: XBRL DOCUMENT

Note 6 - Intangible Assets

9 Months Ended

Sep. 30, 2020

Goodwill and Intangible Assets Disclosure [Text Block]

6.	Intangible Assets

Intangible assets as of September 30, 2020 and December 31, 2019 consisted of the following:

			Nine Months Ended September 30, 2020
	Gross Value		Less: Accumulated Currency Translation Adjustment			Less: Current Period Impairment Charge			Less: Accumulated Amortization			Net Book Value		Weighted Average Useful Life
Developed technology	$	93,953	$	(2,766	)	$	(1,025	)	$	(12,919	)	$	77,243	15
In-process research & development		5,006		(1,120	)		-			-			3,886	Indefinite
Customer relationships		9,000		-			-			(568	)		8,432	10
Distributor relationships		4,700		(415	)		-			(4,285	)		-	5
Patents		1,000		(167	)		-			(602	)		231	16
Tradenames		5,200		-			-			(701	)		4,499	5
Total	$	118,859	$	(4,468	)	$	(1,025	)	$	(19,075	)	$	94,291	13

			Year Ended December 31, 2019
	Gross Value		Less: Accumulated Currency Translation Adjustment			Less: Current Period Impairment Charge			Less: Accumulated Amortization			Net Book Value		Weighted Average Useful Life
Developed technology	$	17,100	$	(2,934	)	$	(389	)	$	(9,657	)	$	4,120	15
In-process research & development		4,406		(1,234	)		-			-			3,172	Indefinite
Distributor relationships		4,700		(415	)		-			(4,285	)		-	5
Patents		1,000		(176	)		-			(531	)		293	16
Elevess Tradename		1,000		-			-			(1,000	)		-	9
Total	$	28,206	$	(4,759	)	$	(389	)	$	(15,473	)	$	7,585	11

The aggregate amortization expense related to intangible assets was $1.9 million and $0.3 million for the three-month periods ended September 30, 2020 and 2019, respectively, and $5.4 million and $0.8 million for the nine-month periods ended September 30, 2020 and 2019, respectively.

In the first quarter of 2020, the Company acquired Parcus Medical and Arthrosurface as discussed in Note 3, which resulted in an increase of $92.9 million of gross value in intangible assets. During the six-month period ended June 30, 2020, the Company determined that it would not pursue CE Mark renewals for certain of its legacy products, which resulted in an impairment of $1.0 million. The impairments are included in the selling, general and administrative expenses on the Company's consolidated statements of operations.

For the quarter ended September 30, 2020, the Company did not identify any impairment triggers.